Histogen Signs License Agreement with Suneva Medical for Cell Conditioned Media-based Aesthetic Products

Posted: March 6, 2012 at 12:45 am

SAN DIEGO, March 5, 2012 /PRNewswire/ --Histogen Inc., a regenerative medicine company, and Suneva Medical, a privately-held aesthetics company, today announced that they have entered into a license agreement for physician-dispensed aesthetic products containing Histogen's proprietary multipotent cell conditioned media (CCM).

Under the terms of this license agreement, Suneva Medical has acquired exclusive U.S. licensing rights to Histogen's multipotent CCM and the ReGenica branded line of products for topical applications in the licensed market. Suneva Medical will manufacture the ReGenica product line and market it to aesthetic practitioners throughout the U.S. Histogen will receive a transfer price on the CCM, as well as royalties on future sales of ReGenica and product line extensions.

"First, let me say that, as the first step in expanding our business, we are very excited about this particular opportunity as the advent of regenerative medicine is upon us. One of our key business objectives is to find novel products that complement our rapidly growing dermal filler business. We believe Histogen's innovative technology coupled with our proven experience of developing and marketing aesthetic products is a winning combination as it enables us to offer our customers a differentiated product line," stated Nicholas Teti, Chairman and Chief Executive Officer of Suneva Medical.

Through Histogen's technology process, which mimics the embryonic environment including conditions of low oxygen and suspension, cells are triggered to become multipotent, and naturally produce proteins associated with skin renewal and scarless healing. The result is a soluble cell conditioned media containing cell-signaling proteins such as KGF, follistatin, stem cell factor, collagens and laminins, which support the epidermal stem cells that renew skin throughout life. In addition, factors associated with scarring, such as TGF-beta, are decreased or nonexistent.

"The applications for this proprietary multipotent CCM within the field of medical aesthetics are numerous and, based upon the way the proteins within the complex signal the body's own stem cells to rejuvenate and regenerate skin, potentially groundbreaking," said Dr. Gail K. Naughton, CEO and Chairman of the Board at Histogen. "This recognition from Suneva's expert team, with a rich background in developing and marketing aesthetics, validates Histogen's technology and supports the fact that it is different from anything currently in the market."

About Histogen Histogen, launched in 2007, seeks to redefine regenerative medicine by developing a series of high value products that do not contain embryonic stem cells or animal components. Through Histogen's proprietary bioreactors that mimic the embryonic environment, including low oxygen and suspension, newborn cells are encouraged to naturally produce the vital proteins and growth factors from which the Company has developed its rich product portfolio. Histogen has two product families a proprietary cell conditioned media, and a human Extracellular Matrix (ECM) material. For more information, please visit http://www.histogen.com.

About Suneva Medical Suneva Medical, Inc. is a privately-held aesthetics company focused on developing, manufacturing and commercializing novel, differentiated products for the dermatology, plastic and cosmetic surgery markets. The Company's long-lasting injectable product is marketed as Artefill in the U.S. and Bellafill in Canada to correct facial wrinkles. For more information visit http://www.sunevamedical.com.


For Histogen Inc.:

Eileen Brandt Phone: (858) 200-9520 ebrandt@histogeninc.com

Read more from the original source:
Histogen Signs License Agreement with Suneva Medical for Cell Conditioned Media-based Aesthetic Products

Related Post

Comments are closed.